Pfizer (PFE) said that the U.S. Food and Drug Administration has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with homologous recombination repair or HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with
By Colin Kellaher Pfizer Inc. on Thursday said a Phase 3 study combining its breast-cancer drug Talzenna with its prostate-cancer drug Xtandi showed a 37% reduction in the risk of disease. | February 16, 2023
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced Tuesday positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI in men with metastatic castration-resistant